Long-term Follow-up of Diabetic Patients From the GLUTADIAB Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: blood sampling.
- Who it may be relevant to
- Registry conditions: Diabetes. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Diabetes and related complications, particularly cardiovascular disease, are associated to exacerbated inflammation, which is characterized by an activation into a pro-inflammatory status of myeloid cells including blood monocytes and tissue macrophages. It is known that monocytes and macrophages sense, integrate and respond to their microenvironment and continually monitor the availability of nutrients in order to adapt their activity and metabolism accordingly. However, the molecular mechanisms driving their activation and switch to a pro-inflammatory phenotype in diabetes are not fully elucidated. The Tricarboxylic Acid cycle is a nexus for multiple nutrient inputs and the generation of Tricarboxylic Acid cycle metabolites is nowadays thought to orient macrophage polarization. Reduced glutamine concentrations have been reported in patients with type 2 diabetes compared to healthy individuals. Ex vivo studies (mainly performed in rodent models) have shown that glutamine catabolism (glutaminolysis) is involved in the activation of macrophages by generating Tricarboxylic Acid cycle intermediates that promote the pro-inflammatory polarization of macrophages. Yet, the link - glutamine catabolism, monocytes polarization and diabetes-related cardiovascular complications - remains unclear. The first phase of this project (GlutaDiab) aimed to clarify this association by quantifying glutamine metabolism in serum and monocytes activation of type 1 and type 2 diabetic patients and investigating the possible correlation with the risk of cardiovascular complications in a transversal cohort. The GlutaDiab2 is the second phase of this project and aims to further investigate the association between glutamine metabolism and cardiovascular risk by collecting follow-up data on cardiovascular events. This longitudinal data will also address the directionality of the association between glutamine metabolism, monocytes activation and cardiovascular risk.
Detailed description
During a scheduled hospitalization or consultation as part of the follow-up of their diabetes, additions of biological samples, which include:
A unique venous blood sampling of 10 tubes (total: 53,5 mL) at a single time during the study
Interventions
- Biological blood sampling
A unique venous blood sampling of 10 tubes: 4 x 7 mL EDTA tubes + 3 x 5 mL EDTA tubes + 2 x 4 mL no additive tubes + 1x 2,5 mL Paxgene tube (total: 53,5 mL) at a single time during the study
Primary outcome measures
- The main objective of the study is to compare the plasma concentrations of glutamine in patients at the first visit (baseline) and the risk of cardiovascular events occurring until the GlutaDiab2 visit [Time frame: inclusion]
Secondary outcome measures (8)
- To study cardiovascular events during follow-up according to glutamine metabolism in patients at baseline [Time frame: inclusion]
- To study cardiovascular events during follow-up according to glutamine metabolism in patients at baseline [Time frame: inclusion]
- To study cardiovascular events during follow-up according to glutamine metabolism in patients at baseline [Time frame: inclusion]
- To study cardiovascular events during follow-up according to the inflammatory status in patients at baseline [Time frame: inclusion]
- To study cardiovascular events during follow-up according to the inflammatory status in patients at baseline [Time frame: inclusion]
- To study cardiovascular events during follow-up according to the inflammatory status in patients at baseline [Time frame: inclusion]
- To study cardiovascular events during follow-up according to the monocyte activation status in patients at baseline [Time frame: inclusion]
- To study glutamine metabolism variations between baseline and follow-up visit according to variation in cardiovascular risk [Time frame: inclusion]
Eligibility criteria
Inclusion criteria
- Person previously enroled in the GLUTADIAB study in group 1 or 2 (cf appendix 1 for GLUTADIAB inclusion criteria)
Exclusion criteria
- Pregnant or breastfeeding woman
- Absence of free and informed consent
- Subject deprived of freedom, subject under a legal protective measure
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 2 centers
- Lariboisière hospital — Paris
- Diabétologie — Paris
Identifiers
NCT: NCT07347613 · 2025-A02804-45